A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott… - … England Journal of …, 2015 - Mass Medical Soc
Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long …
MJ Koren, RP Giugliano, FJ Raal, D Sullivan… - Circulation, 2014 - Am Heart Assoc
Background—Evolocumab (AMG 145), a monoclonal antibody against proprotein
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein …
Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies
Background: Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein
convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol …
convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol …
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab
MJ Koren, P Lundqvist, M Bolognese, JM Neutel… - Journal of the American …, 2014 - jacc.org
Objectives: The aim of this study was to compare biweekly and monthly evolocumab with
placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial …
placebo and oral ezetimibe in patients with hypercholesterolemia in a phase III trial …
Evolocumab and clinical outcomes in patients with cardiovascular disease
MS Sabatine, RP Giugliano, AC Keech… - New England journal …, 2017 - Mass Medical Soc
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …
Long-term low-density lipoprotein cholesterol–lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: Results up to 4 years …
MJ Koren, MS Sabatine, RP Giugliano… - JAMA …, 2017 - jamanetwork.com
Importance The Open-Label Study of Long-term Evaluation Against LDL-C (OSLER-1)
evaluated the durability of long-term efficacy and safety during long-term therapy with …
evaluated the durability of long-term efficacy and safety during long-term therapy with …
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies …
EA Stein, RP Giugliano, MJ Koren, FJ Raal… - European heart …, 2014 - academic.oup.com
Aims Prior trials with monoclonal antibodies to proprotein convertase subtilizin/kexin type 9
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
(PCSK9) reported robust low density lipoprotein cholesterol (LDL-C) reductions. However …
[HTML][HTML] A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk
A Kiyosue, N Honarpour, C Kurtz, A Xue… - The American journal of …, 2016 - Elsevier
Evolocumab (AMG 145), a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This …
Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 …
JG Robinson, BS Nedergaard, WJ Rogers, J Fialkow… - Jama, 2014 - jamanetwork.com
Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9,
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …